gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
about
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infectionDisruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic ResistanceAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionAlterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.Hypervirulent Clostridium difficile strains in hospitalized patients, CanadaCharacterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanPredominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern TaiwanMolecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.Characteristics of patients with Clostridium difficile infection in Taiwan.The emergence of Clostridium difficile PCR-ribotype 001 in Slovakia.Fluoroquinolone resistance does not impose a cost on the fitness of Clostridium difficile in vitro.Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.Fluoroquinolone resistance and Clostridium difficile, Germany.Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.Plasmid-related quinolone resistance determinants in epidemic Vibrio parahaemolyticus, uropathogenic Escherichia coli, and marine bacteria from an aquaculture area in Chile.gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.In vivo selection of moxifloxacin-resistant Clostridium difficile.Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik's Cube of Clinical Microbiology?Community-acquired infection with hypervirulent Clostridium difficile isolates that carry different toxin and antibiotic resistance loci: a case report.Epidemiological Features of Clostridium difficile Colonizing the Intestine of Jordanian Infants.Detection of cross-infection associated to a Brazilian PCR-ribotype of Clostridium difficile in a university hospital in Rio de Janeiro, Brazil.Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.
P2860
Q26767079-E19BBB51-0795-4F67-A4AD-848CC6FE978DQ26771995-CD69CD00-0AED-4952-96F6-032CEA2A0B94Q28084026-F4BB9EF1-3A5F-4D84-AE4E-F839032CB4E9Q33805682-2EE95064-B40B-464A-9528-1FDC24325F1EQ34046334-FCEE7F75-1F82-427F-9DF9-DE205D4B01BCQ34737651-AC9050AF-EA66-4418-A977-F3B058D6D4D9Q35675014-967450A9-3DE4-4433-A409-9C876114DB2FQ35877207-A56D790C-6FED-45CE-B6A8-4786D18B336BQ36086377-B44773D0-C237-4635-8728-BEB507C3C5E1Q36197566-CFFBC338-BE12-464A-9823-F04E6245AF02Q37204206-09582287-C51B-42A2-A577-9ED8C989492CQ37544845-1AA3991F-00D0-491D-A5B1-0644C3682D58Q38837163-06B34F8A-6A3A-4210-A9FB-758F8D7315A8Q40265282-E73ED8B1-B7E7-4E74-B3A9-B0EDC3278625Q41225310-6285FD81-8B2C-4E99-95BD-04C748B93D85Q41585335-179D5A60-DDC6-4A7C-8587-A291ABD0E6EEQ41839829-C1E131AF-D61D-49D8-8064-66CE8F44655EQ41983841-94908277-5498-457F-B887-BE4CC8002CBCQ42116391-5D9051D3-672F-4268-B65A-0535CCAF0596Q42218073-523DBAB3-DFD5-4F09-BECC-C038940CDEDFQ42676032-0CB1B9A0-B3BA-4621-A61C-AF396A92967AQ43164995-C85C7E14-E7CF-42E1-9176-4FE7EDC1DE75Q46237911-6AFEFA3A-529D-42E0-A1A6-1E42DE7548C1Q46266852-68E27640-6FE2-4168-A9F0-0D08A6F2BE52Q46793647-459D6C39-8BF6-4648-884A-2489A20FDBA1Q49405828-3D16E681-A36D-49EC-A75D-10528805AAD0Q51761286-3B97D559-456C-4172-B67F-903D6E7A8E43Q53692769-74A91FFE-B805-4D32-959A-826B0DD9FBD7Q55430134-09988126-2395-466F-8B66-DE2439E2E724
P2860
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@en
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@nl
type
label
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@en
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@nl
prefLabel
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@en
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@nl
P2093
P2860
P1476
gyrA and gyrB mutations are im ...... acin in Clostridium difficile.
@en
P2093
Béatrice Burghoffer
Frédéric Barbut
Jacques Tankovic
Jean-Claude Petit
Larbi Dridi
P2860
P304
P356
10.1128/AAC.46.11.3418-3421.2002
P407
P577
2002-11-01T00:00:00Z